Drug Approval | August 12, 2021
SAB Biotherapeutics nonclinical data indicates SAB-185 neutralizes Delta and Lambda SARS-CoV-2 Variants
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
The sensors have been tested for their different level of strains like micro and large scale motion monitoring and have potential applications in biomedical devices, skin electronics, and minimally invasive surgery
The profits were bolstered by the Boehringer Ingelheim MEK program income
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Deal signed with AOP Orphan for US commercial rights
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Subscribe To Our Newsletter & Stay Updated
